BioCity Heralds New Phase of Growth with CFO Appointment
News Nov 04, 2015
BioCity has appointed Paul Oliver as chief financial officer to drive the next stage of growth across its four sites in England and Scotland.
Paul Oliver joins BioCity, having previously been chief financial officer of the FTSE 250 pharmaceutical company Vectura Group plc where, among other significant achievements, he helped oversee a major €130m international acquisition and a £52m equity placing on the London Stock Exchange.
On joining BioCity, Paul said: "I'm excited to be joining such a unique organization. BioCity is exemplary in the way it supports, nurtures and invests in early stage biotech companies and I look forward to helping BioCity continue the excellent progress it has made to date."
Speaking about Paul Oliver's appointment, BioCity CEO Glenn Crocker said: "We are delighted to welcome Paul to BioCity at this exciting period in the Company's growth. Paul is an established and well-regarded CFO who has gained considerable relevant experience within the UK pharmaceutical industry. His strong financial control, market knowledge and transaction experience will be a considerable asset for BioCity.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019